Herbert I. Hurwitz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Herbert I. Hurwitz has a total of 308 co-authors. Here are the top co-authors by number of shared publications:
Nicolas Sommer
40 shared publicationsAlan Nicholas
38 shared publicationsChristoph Mancao
38 shared publicationsJohanna C. Bendell
38 shared publicationsJohn J. Lee
38 shared publicationsMark D. Starr
38 shared publications
Latest Publications
- Open Access
- 9 January 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Characterization of the Biological Variability of the Angiome Biomarkers over Time in Healthy Participants
Supplementary Figure S1 shows biomarker variability over time.
- 9 January 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Characterization of the Biological Variability of the Angiome Biomarkers over Time in Healthy Participants
Supplementary Figure S1 shows biomarker variability over time.
- Open Access
- 9 January 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Characterization of the Biological Variability of the Angiome Biomarkers over Time in Healthy Participants
Supplementary Figure S3 shows homoscedasticity and normality of residuals.
- 9 January 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Characterization of the Biological Variability of the Angiome Biomarkers over Time in Healthy Participants
Supplementary Figure S3 shows homoscedasticity and normality of residuals.
- Open Access
- 9 January 2025
- Published by American Association for Cancer Research (AACR)
Data from Characterization of the Biological Variability of the Angiome Biomarkers over Time in Healthy Participants
Background:Biomarker analyses are an integral part of cancer research. Despite the intense efforts to identify and characterize biomarkers in patients with cancer, little is known regarding the natural variation of biomarkers in healthy populations. Here we conducted a clinical study to evaluate the natural variability of biomarkers over time in healthy participants.Methods:The angiome multiplex array, a panel of 25 circulating protein biomarkers, was assessed in 28 healthy participants across eight timepoints over the span of 60 days. We utilized the intraclass correlation coefficient (ICC) to quantify the reliability of the biomarkers. Adjusted ICC values were calculated under the framework of a linear mixed-effects model, taking into consideration age, sex, body mass index, fasting status, and sampling factors.Results:ICC was calculated to determine the reliability of each biomarker. Hepatocyte growth factor was the most stable marker (ICC = 0.973), while platelet-derived growth factor (PDGF)-BB was the most variable marker (ICC = 0.167). In total, ICC analyses revealed that 22 out of 25 measured biomarkers display good (≥0.4) to excellent (>0.75) ICC values. Three markers (PDGF-BB, TGFβ1, PDGF-AA) had ICC values <0.4. Greater age was associated with higher IL6 (P = 0.0114). Higher body mass index was associated with higher levels of IL6 (P = 0.0003) and VEGF-R3 (P = 0.0045).Conclusions:Of the 25 protein biomarkers measured over this short time period, 22 markers were found to have good or excellent ICC values, providing additional validation for this biomarker assay.Impact:These data further support the validation of the angiome biomarker assay and its application as an integrated biomarker in clinical trial testing.
- 9 January 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Characterization of the Biological Variability of the Angiome Biomarkers over Time in Healthy Participants
Background:Biomarker analyses are an integral part of cancer research. Despite the intense efforts to identify and characterize biomarkers in patients with cancer, little is known regarding the natural variation of biomarkers in healthy populations. Here we conducted a clinical study to evaluate the natural variability of biomarkers over time in healthy participants.Methods:The angiome multiplex array, a panel of 25 circulating protein biomarkers, was assessed in 28 healthy participants across eight timepoints over the span of 60 days. We utilized the intraclass correlation coefficient (ICC) to quantify the reliability of the biomarkers. Adjusted ICC values were calculated under the framework of a linear mixed-effects model, taking into consideration age, sex, body mass index, fasting status, and sampling factors.Results:ICC was calculated to determine the reliability of each biomarker. Hepatocyte growth factor was the most stable marker (ICC = 0.973), while platelet-derived growth factor (PDGF)-BB was the most variable marker (ICC = 0.167). In total, ICC analyses revealed that 22 out of 25 measured biomarkers display good (≥0.4) to excellent (>0.75) ICC values. Three markers (PDGF-BB, TGFβ1, PDGF-AA) had ICC values <0.4. Greater age was associated with higher IL6 (P = 0.0114). Higher body mass index was associated with higher levels of IL6 (P = 0.0003) and VEGF-R3 (P = 0.0045).Conclusions:Of the 25 protein biomarkers measured over this short time period, 22 markers were found to have good or excellent ICC values, providing additional validation for this biomarker assay.Impact:These data further support the validation of the angiome biomarker assay and its application as an integrated biomarker in clinical trial testing.
- Open Access
- 9 January 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Characterization of the Biological Variability of the Angiome Biomarkers over Time in Healthy Participants
Supplementary Figure S2 show intra- and inter-participants variability.
- 9 January 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Characterization of the Biological Variability of the Angiome Biomarkers over Time in Healthy Participants
Supplementary Figure S2 show intra- and inter-participants variability.
- Open Access
- 9 January 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Characterization of the Biological Variability of the Angiome Biomarkers over Time in Healthy Participants
Supplementary Table S3 shows the association of BMI with biomarker levels.
- 9 January 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Characterization of the Biological Variability of the Angiome Biomarkers over Time in Healthy Participants
Supplementary Table S3 shows the association of BMI with biomarker levels.
- Open Access
- 9 January 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Characterization of the Biological Variability of the Angiome Biomarkers over Time in Healthy Participants
Supplementary Table S4 shows the association of fasting or fed status with biomarker levels.
- 9 January 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Characterization of the Biological Variability of the Angiome Biomarkers over Time in Healthy Participants
Supplementary Table S4 shows the association of fasting or fed status with biomarker levels.
- Open Access
- 9 January 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from Characterization of the Biological Variability of the Angiome Biomarkers over Time in Healthy Participants
Supplementary Table S5 shows three potential measures of variance.
- 9 January 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from Characterization of the Biological Variability of the Angiome Biomarkers over Time in Healthy Participants
Supplementary Table S5 shows three potential measures of variance.
- Open Access
- 9 January 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Characterization of the Biological Variability of the Angiome Biomarkers over Time in Healthy Participants
Supplemental Table S1 shows the association of age with biomarker levels.
- 9 January 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Characterization of the Biological Variability of the Angiome Biomarkers over Time in Healthy Participants
Supplemental Table S1 shows the association of age with biomarker levels.
- Open Access
- 9 January 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Characterization of the Biological Variability of the Angiome Biomarkers over Time in Healthy Participants
Supplementary Table S2 shows the association of sex with biomarker levels.
- 9 January 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Characterization of the Biological Variability of the Angiome Biomarkers over Time in Healthy Participants
Supplementary Table S2 shows the association of sex with biomarker levels.
- 14 October 2024
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 34 (1) , 93-99
Characterization of the Biological Variability of the Angiome Biomarkers over Time in Healthy Participants
Background: Biomarker analyses are an integral part of cancer research. Despite the intense efforts to identify and characterize biomarkers in patients with cancer, little is known regarding the natural variation of biomarkers in healthy populations. Here we conducted a clinical study to evaluate the natural variability of biomarkers over time in healthy participants. Methods: The angiome multiplex array, a panel of 25 circulating protein biomarkers, was assessed in 28 healthy participants across eight timepoints over the span of 60 days. We utilized the intraclass correlation coefficient (ICC) to quantify the reliability of the biomarkers. Adjusted ICC values were calculated under the framework of a linear mixed-effects model, taking into consideration age, sex, body mass index, fasting status, and sampling factors. Results: ICC was calculated to determine the reliability of each biomarker. Hepatocyte growth factor was the most stable marker (ICC = 0.973), while platelet-derived growth factor (PDGF)-BB was the most variable marker (ICC = 0.167). In total, ICC analyses revealed that 22 out of 25 measured biomarkers display good (≥0.4) to excellent (>0.75) ICC values. Three markers (PDGF-BB, TGFβ1, PDGF-AA) had ICC values <0.4. Greater age was associated with higher IL6 (P = 0.0114). Higher body mass index was associated with higher levels of IL6 (P = 0.0003) and VEGF-R3 (P = 0.0045). Conclusions: Of the 25 protein biomarkers measured over this short time period, 22 markers were found to have good or excellent ICC values, providing additional validation for this biomarker assay. Impact: These data further support the validation of the angiome biomarker assay and its application as an integrated biomarker in clinical trial testing.
- 14 October 2024
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 34 (1) , 93-99
Characterization of the Biological Variability of the Angiome Biomarkers over Time in Healthy Participants
Background: Biomarker analyses are an integral part of cancer research. Despite the intense efforts to identify and characterize biomarkers in patients with cancer, little is known regarding the natural variation of biomarkers in healthy populations. Here we conducted a clinical study to evaluate the natural variability of biomarkers over time in healthy participants. Methods: The angiome multiplex array, a panel of 25 circulating protein biomarkers, was assessed in 28 healthy participants across eight timepoints over the span of 60 days. We utilized the intraclass correlation coefficient (ICC) to quantify the reliability of the biomarkers. Adjusted ICC values were calculated under the framework of a linear mixed-effects model, taking into consideration age, sex, body mass index, fasting status, and sampling factors. Results: ICC was calculated to determine the reliability of each biomarker. Hepatocyte growth factor was the most stable marker (ICC = 0.973), while platelet-derived growth factor (PDGF)-BB was the most variable marker (ICC = 0.167). In total, ICC analyses revealed that 22 out of 25 measured biomarkers display good (≥0.4) to excellent (>0.75) ICC values. Three markers (PDGF-BB, TGFβ1, PDGF-AA) had ICC values <0.4. Greater age was associated with higher IL6 (P = 0.0114). Higher body mass index was associated with higher levels of IL6 (P = 0.0003) and VEGF-R3 (P = 0.0045). Conclusions: Of the 25 protein biomarkers measured over this short time period, 22 markers were found to have good or excellent ICC values, providing additional validation for this biomarker assay. Impact: These data further support the validation of the angiome biomarker assay and its application as an integrated biomarker in clinical trial testing.